Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Completes Acquisition of Solventum’s Purification and Filtration Business
Summary
Thermo Fisher Scientific Inc. has completed the acquisition of Solventum Corporation's purification and filtration business for approximately $4.0 billion in cash. The acquired business, now part of Thermo Fisher's Life Sciences Solutions segment, is expected to generate about $750 million in revenue for the full year 2025. The acquisition is expected to be initially dilutive to adjusted earnings per share (EPS) by $0.06 in the first year, with anticipated synergies of $125 million in adjusted operating income by year five. This acquisition strengthens Thermo Fisher’s bioprocessing offerings and expands its reach into adjacent markets.
Profitelligence Alerts
Get alerts for TMO
Be first to know when Thermo Fisher Scientific Inc. files with the SEC.
Filing Categories
Advertisement
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a world-leading biotechnology company that provides essential tools and services for life sciences, biotechnology, pharmaceutical, and healthcare industries. Renowned for its extensive portfolio, the company specializes in offering innovative laboratory products, analytical instruments, and software solutions critical for research, diagnostics, and clinical applications. Thermo Fisher enables scientists to perform complex experiments with cutting-edge technology, from DNA sequencing and cell analysis to clinical diagnostics and specialty chemicals. Serving a vast array of sectors, the company impacts fields such as diagnostics, genetic engineering, and environmental monitoring. Its strategic acquisitions and collaborations strengthen its market presence, making it a go-to partner for scientific advancements and innovation. With operations spanning over 50 countries, Thermo Fisher plays a pivotal role in driving scientific discovery and improving health outcomes globally.
Official SEC Documents
Advertisement